Amphastar Pharmaceuticals
AMPH
245 hedge funds and large institutions have $1.8B invested in Amphastar Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 80 increasing their positions, 90 reducing their positions, and 22 closing their positions.
123% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 22
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
59% more capital invested
Capital invested by funds: $1.13B → $1.8B (+$671M)
48% more call options, than puts
Call options by funds: $2.77M | Put options by funds: $1.87M
12% more funds holding
Funds holding: 218 → 245 (+27)
2.01% more ownership
Funds ownership: 63.06% → 65.07% (+2%)
11% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 90
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$46.9M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$20.7M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$11.4M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$7.94M |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$6.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$21.2M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$10.5M |
| 3 |
MIIM
Mesirow Institutional Investment Management
Chicago,
Illinois
|
-$8.7M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7.2M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$7.02M |
AMPH Hedge Fund Activity: Q2 2023 in Review
245 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2023, worth a combined $1.8B — up 59% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new AMPH positions and 22 closed out — a net gain of 27 holders — while 80 added to existing stakes and 90 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $46.9M. The largest seller was BlackRock, cutting an estimated $21.2M.
- 245 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2023, up from 218 in Q1 2023.
- Funds reported $1.8B of Amphastar Pharmaceuticals stock for Q2 2023, up 59% quarter-over-quarter.
- 49 funds opened new Amphastar Pharmaceuticals positions in Q2 2023 and 22 closed out, a net change of +27 holders.
- The largest Amphastar Pharmaceuticals buyer in Q2 2023 was Neuberger Berman Group, an estimated $46.9M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2023 was BlackRock, an estimated $21.2M sold.
Based on aggregated 13F filings for Q2 2023.